Results 21 to 30 of about 33,878 (250)

Hemianopsia in Dementia With Lewy Bodies [PDF]

Archives of Neurology, 1998
To describe the pathologic changes that caused a left homonymous hemianopsia in a patient with dementia with Lewy bodies.Report of a case and postmortem studies.A 66-year-old woman experienced parkinsonism and left homonymous hemianopsia early in the course of a rapidly progressive dementia that culminated in death only 21 months after the onset of her
K, Bashir, R J, Elble, M, Ghobrial, R G, Struble   +3 more
openaire   +2 more sources

Dementia with Lewy Bodies.

Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics, 2000
Dementia with Lewy bodies (DLB), the second most frequent cause of primary degenerative dementias following Alzheimer's disease, has been increasingly recognized since the proposal of the consensus name and clinical diagnostic criteria. Although DLB overlaps in clinical, pathological, and genetic features with Alzheimer's disease and Parkinson's ...
openaire   +3 more sources

Introduction of an assessment toolkit associated with increased rate of DLB diagnosis

Alzheimer’s Research & Therapy, 2021
Background Dementia with Lewy bodies (DLB) and dementia in Parkinson’s disease (PDD) are recognised to be under-recognised in clinical practice in the UK, with only one third to a half of expected cases diagnosed.
A. Surendranathan, J. Kane, A. Bentley, S. Barker, R. McNally, C. Bamford, J.-P. Taylor, A. Thomas, I. McKeith, D. Burn, J. T. O’Brien   +10 more
doaj   +1 more source

Renal Failure in Dementia with Lewy Bodies Presenting as Catatonia

Case Reports in Neurology, 2013
Catatonia, originally described by Karl Kahlbaum in 1874, may be regarded as a set of clinical features found in a subtype of schizophrenia, but the syndrome may also stem from organic causes including vascular parkinsonism, brain masses, globus pallidus
Robert Fekete
doaj   +1 more source

Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases.

PLoS ONE, 2013
ObjectiveMost neurodegenerative diseases contain hyperphosphorylated Tau [p-Tau]. We examined for the first time epitopes at which Tau is hyperphosphorylated in Parkinson's disease, dementia with Lewy bodies and Alzheimer's disease, and also select Tau ...
Valeriy Duka, Jae-Hoon Lee, Joel Credle, Jonathan Wills, Adam Oaks, Ciaran Smolinsky, Ketul Shah, Deborah C Mash, Eliezer Masliah, Anita Sidhu   +9 more
doaj   +1 more source

Dementia with Lewy bodies research consortia: A global perspective from the ISTAART Lewy Body Dementias Professional Interest Area working group

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2021
Dementia with Lewy bodies (DLB) research has seen a significant growth in international collaboration over the last three decades. However, researchers face a challenge in identifying large and diverse samples capable of powering longitudinal studies and
Fabrizia D'Antonio, Joseph P.M. Kane, Agustin Ibañez, Simon J.G. Lewis, Richard Camicioli, Huali Wang, Yueyi Yu, Jing Zhang, Yong Ji, Miguel Germán Borda, Rukmini Mridula Kandadai, Claudio Babiloni, Laura Bonanni, Manabu Ikeda, Bradley F. Boeve, James B. Leverenz, Dag Aarsland, the ISTAART Lewy body dementias Consortia Working Group   +17 more
doaj   +1 more source

Prodromal dementia with Lewy bodies [PDF]

Psychological Medicine, 2014
BackgroundThe clinical condition of dementia is now recognized as a diagnosis that can only be applied too late in the disease process to be useful for therapeutic approaches centring on disease modification. As a result, in recent years increasing attention has been given to mild cognitive impairment (MCI) and the diagnosis of prodromal dementia. This
P C, Donaghy, J T, O'Brien, A J, Thomas
openaire   +2 more sources

Five‐Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To provide a comprehensive description of disease progression in synuclein seeding assay (SAA) positive sporadic Parkinson Disease participants, using Neuronal Synuclein Disease integrated biological and functional impairment staging framework.
Paulina Gonzalez‐Latapi, Caroline Gochanour, Seung Ho Choi, Hyunkeun Cho, Chelsea Caspell‐Garcia, Christopher Coffey, Michael Brumm, David‐Erick Lafontant, Yuge Xiao, Thomas Tropea, John Seibyl, Caroline Tanner, Charles S. Venuto, Karl Kieburtz, Lana M. Chahine, Kathleen L. Poston, Andrew Siderowf, Kenneth Marek, Tanya Simuni, The Parkinson's Progression Markers Initiative   +19 more
wiley   +1 more source

Posterior Cortical Atrophy in the Asia‐Pacific: A Report From the PCA Asian Workgroup

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Posterior Cortical Atrophy (PCA) is a distinct dementia syndrome primarily affecting spatial abilities and visual processing. It is associated with degeneration in the posterior part of the brain. PCA is subclassified into PCA‐pure and PCA‐plus syndromes based on consensus criteria.
Yuttachai Likitjaroen, Ya‐Ting Chang, Levinia Lim, Pai‐Yi Chiu, Jung‐Lung Hsu, SangYun Kim, Wataru Narita, Na Young Ryoo, Kyoko Suzuki, Nagaendran Kandiah, Sebastian Crutch, Ming‐Chyi Pai   +11 more
wiley   +1 more source

Dementia in Parkinson's Disease Correlates with α-Synuclein Pathology but Not with Cortical Astrogliosis

Parkinson's Disease, 2012
Dementia is a common feature in Parkinson’s disease (PD) and is considered to be the result of limbic and cortical Lewy bodies and/or Alzheimer changes.
Simone A. van den Berge, Josta T. Kevenaar, Jacqueline A. Sluijs, Elly M. Hol   +3 more
doaj   +1 more source